bioMérieux is a French company founded in 1963, operating within the manufacturing sector, specifically in the biotechnology and pharmaceuticals industries. With over 10,000 employees and significant revenue, the company specializes in developing innovative solutions for microbiological testing, particularly in the context of advanced therapeutic medicinal products such as cell and gene therapies. A recent document highlights bioMérieux's focus on mycoplasma detection, a critical aspect of ensuring the safety of biologics. The company offers the BIOFIRE® MYCOPLASMA test, which allows for rapid detection of over 130 species of mycoplasma within approximately one hour, significantly reducing the time required compared to traditional culture methods that can take 28 days or more. This innovative testing solution is designed to facilitate in-house testing, thereby minimizing outsourcing costs and expediting the release of therapeutic products. bioMérieux's expertise in microbiological testing positions it as a key player in enhancing patient safety and efficiency in the biopharmaceutical sector.